Missing/wrong data?
Log in to edit
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
scientific article published on September 2014
Author/s
author: Andrew L. Kung, Kimberly Stegmaier, Louis Chesler, Nathanael Gray, Takaomi Sanda
Work details
Publication date
September 1, 2014
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.